Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Ascending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
59572-0501-00 59572-0501 Pomalidomide Pomalyst 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use
59572-0501-21 59572-0501 Pomalidomide Pomalyst 1.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use
59572-0502-00 59572-0502 Pomalidomide Pomalyst 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use
59572-0502-21 59572-0502 Pomalidomide Pomalyst 2.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use
59572-0503-00 59572-0503 Pomalidomide Pomalyst 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use
59572-0503-21 59572-0503 Pomalidomide Pomalyst 3.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use
59572-0504-00 59572-0504 Pomalidomide Pomalyst 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use
59572-0504-21 59572-0504 Pomalidomide Pomalyst 4.0 mg/1 Immunotherapy Immunomodulator Thalidomide Analog Oral Feb. 18, 2013 In Use
59572-0515-01 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-02 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0515-03 59572-0515 idecabtagene vicleucel Abecma 300000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous March 26, 2021 In Use
59572-0705-30 59572-0705 Enasidenib mesylate Idhifa 50.0 mg/1 Chemotherapy Enzyme Inhibitor IDH2 Oral Aug. 1, 2017 In Use
59572-0710-30 59572-0710 Enasidenib mesylate Idhifa 100.0 mg/1 Chemotherapy Enzyme Inhibitor IDH2 Oral Aug. 1, 2017 In Use
59572-0711-01 59572-0711 Luspatercept REBLOZYL 25.0 mg/1 Ancillary Therapy Erythropoiesis-Stimulating Agent Subcutaneous Nov. 8, 2019 In Use
59572-0720-12 59572-0720 Fedratinib Hydrochloride Inrebic 100.0 mg/1 Chemotherapy Enzyme Inhibitor JAK2, FLT3 Oral Aug. 16, 2019 In Use
59572-0730-07 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0730-14 59572-0730 azacitidine ONUREG 200.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
59572-0740-07 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 18, 2020 In Use
59572-0740-14 59572-0740 azacitidine ONUREG 300.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
59572-0775-01 59572-0775 Luspatercept Reblozyl 75.0 mg/1 Immunotherapy Erythropoiesis-Stimulating Agent Subcutaneous Nov. 8, 2019 In Use
59572-0983-01 59572-0983 Romidepsin Istodax Chemotherapy Enzyme Inhibitor HDAC Jan. 4, 2010 In Use
59572-0984-01 59572-0984 Romidepsin Istodax Chemotherapy Enzyme Inhibitor HDAC Intravenous Jan. 4, 2010 In Use
59630-0222-07 59630-0222 Naldemedine SYMPROIC 0.2 mg/1 Ancillary Therapy Opioid Antagonist Oral July 5, 2018 Dec. 31, 2020 No Longer Used
59630-0222-30 59630-0222 Naldemedine SYMPROIC 0.2 mg/1 Ancillary Therapy Opioid Antagonist Oral July 5, 2018 Dec. 31, 2020 No Longer Used
59630-0222-90 59630-0222 Naldemedine SYMPROIC 0.2 mg/1 Ancillary Therapy Opioid Antagonist Oral July 5, 2018 Dec. 31, 2020 No Longer Used

Found 10,000 results in 10 milliseconds — Export these results